UK small-cap RNS · 7 Nov 2025

Every announcement of UK small & mid caps under £2bn. The ones that started or moved a situation are marked – a click opens it.

Sort: Newest · Largest companies

17:15

Mortgage Advice Bureau (Holdings) MAB1 £220m
Holding(s) in Company Holding
09:01

Critical Metals CRTM £83m
Final Results Results
Final results show cash of only £7,167 after a difficult year, with exploration halted, delayed restructuring and no resource estimate yet. Recapitalisation and a stronger board are offsets, but funding remains a concern.

Balance-sheet stress / refinancing outlook mixedfirst since Oct 2023 +0.0% on the day

Moved: Temporary suspension of listing: Suspended from Official List 3 Nov 2025 → Reinstatement application lodged with FCA · new: Molulu resource estimate and PEA – Exploration halted; geological data analysis planned · new: Additional funding requirement – Planned, cash minimal
08:00

Blencowe Resources BRES £31m
CEO Interview Board change
Blencowe Resources Plc (LSE: BRES) provides a summary of key points discussed by Chief Executive Officer Mike Ralston in a recorded interview with respected market commentator Charles Archer.

Project milestones outlook positivefirst since Oct 2023 +9.7% on the day

Moved: Orom-Cross DFS and JORC update: Infill drilling complete; JORC update in progress → JORC due in ~2 weeks; DFS targeted late-November · Lyan and Beehive exploration assays: Drilling concluded; assays pending → Updates now expected post-DFS
07:00

Trellus Health TRLS £0.5m
Contract signed with second leading CRO
Second 12-month TrialSet contract with a large CRO, covering two late-stage immunology trials, turns preferred-vendor status into revenue. But the CEO says it does not extend the runway beyond early December 2025.

Balance-sheet stress / refinancing outlook mixed +0.0% on the day

Moved: Cash runway and fundraising: Runway still early December despite new contract → Runway still early December; fundraising options under exploration · New CRO collaborations: One contract signed; second at preferred vendor → Two CRO contracts signed; second starts by year end
07:00

Scancell Holdings SCLP £124m
Research Update
Scancell holds oral presentation of positive Phase 2 data on Immunobody® iSCIB1+ in late-stage melanoma at SITC 2025

Project milestones outlook positive +1.5% on the day

Moved: new: iSCIB1+ melanoma registration path – Phase 2 data presented; development accelerated